

# Mark E Robson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3884281/publications.pdf>

Version: 2024-02-01

273  
papers

34,726  
citations

4146

87  
h-index

4015

176  
g-index

281  
all docs

281  
docs citations

281  
times ranked

34726  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473
2	Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 523-533.	27.0	2,256
3	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with <i>BRCA1</i> or <i>BRCA2</i> mutations and advanced breast cancer: a proof-of-concept trial. <i>Lancet</i> , The, 2010, 376, 235-244.	13.7	1,584
4	Risk-Reducing Salpingo-oophorectomy in Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation. <i>New England Journal of Medicine</i> , 2002, 346, 1609-1615.	27.0	1,363
5	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 443-453.	27.0	1,205
6	Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk. <i>New England Journal of Medicine</i> , 2015, 372, 2243-2257.	27.0	764
7	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	6.2	711
8	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018, 34, 427-438.e6.	16.8	633
9	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. <i>Journal of Clinical Oncology</i> , 2015, 33, 3660-3667.	1.6	603
10	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. <i>Cell Stem Cell</i> , 2017, 21, 374-382.e4.	11.1	578
11	Tamoxifen and risk of contralateral breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: a case-control study. <i>Lancet</i> , The, 2000, 356, 1876-1881.	13.7	538
12	Risk-Reducing Salpingo-Oophorectomy for the Prevention of <i>BRCA1</i> - and <i>BRCA2</i> -Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 1331-1337.	1.6	522
13	Pathology of Breast and Ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> (CIMBA). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 134-147.	2.5	513
14	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
15	OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline <i>BRCA</i> mutation and HER2-negative metastatic breast cancer. <i>Annals of Oncology</i> , 2019, 30, 558-566.	1.2	493
16	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <i>Nature Medicine</i> , 2019, 25, 1928-1937.	30.7	485
17	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	428
18	Genome doubling shapes the evolution and prognosis of advanced cancers. <i>Nature Genetics</i> , 2018, 50, 1189-1195.	21.4	411

#	ARTICLE	IF	CITATIONS
19	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 286-295.	1.6	397
20	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	7.4	390
21	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. <i>Journal of Clinical Oncology</i> , 2010, 28, 893-901.	1.6	389
22	Impairment of <i>BRCA1</i> -Related DNA Double-Strand Break Repair Leads to Ovarian Aging in Mice and Humans. <i>Science Translational Medicine</i> , 2013, 5, 172ra21.	12.4	384
23	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , 2020, 52, 1219-1226.	21.4	367
24	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 825.	7.4	366
25	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
26	Oral Contraceptives and the Risk of Breast Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1773-1779.	6.3	318
27	Tumour lineage shapes <i>BRCA</i> -mediated phenotypes. <i>Nature</i> , 2019, 571, 576-579.	27.8	295
28	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	286
29	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.	1.6	276
30	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. <i>JAMA Oncology</i> , 2016, 2, 104.	7.1	270
31	Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 Families. <i>Journal of Clinical Oncology</i> , 2020, 38, 674-685.	1.6	270
32	Germline <i>BRCA</i> Mutations Denote a Clinicopathologic Subset of Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2115-2121.	7.0	263
33	A combined analysis of outcome following breast cancer: differences in survival based on <i>BRCA1/BRCA2</i> mutation status and administration of adjuvant treatment. <i>Breast Cancer Research</i> , 2003, 6, R8-R17.	5.0	262
34	Counselling framework for moderate-penetrance cancer-susceptibility mutations. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 581-588.	27.6	258
35	Genome-Wide Association Study in <i>BRCA1</i> Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	3.5	244
36	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	242

#	ARTICLE	IF	CITATIONS
37	An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known <i>BRCA</i> Mutation: Clinical Descriptors, Treatment Implications, and Future Directions. <i>Oncologist</i> , 2011, 16, 1397-1402.	3.7	227
38	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	2.5	224
39	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
40	Management of an Inherited Predisposition to Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 154-162.	27.0	222
41	Multiplex Genetic Testing for Cancer Susceptibility: Out on the High Wire Without a Net?. <i>Journal of Clinical Oncology</i> , 2013, 31, 1267-1270.	1.6	217
42	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. <i>Journal of Clinical Oncology</i> , 2016, 34, 2141-2147.	1.6	204
43	Fallopian Tube and Primary Peritoneal Carcinomas Associated With <i>BRCA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2003, 21, 4222-4227.	1.6	199
44	<i>BRCA</i> Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 433-438.	1.6	194
45	Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6708-6720.	7.0	194
46	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With <i>BRCA</i> Mutations. <i>JAMA Oncology</i> , 2016, 2, 1434.	7.1	189
47	Shared Genetic Susceptibility to Breast Cancer, Brain Tumors, and Fanconi Anemia. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1548-1551.	6.3	183
48	Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 2080-2106.	1.6	178
49	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1067-1074.	6.3	170
50	Identification of germline genetic mutations in patients with pancreatic cancer. <i>Cancer</i> , 2015, 121, 4382-4388.	4.1	167
51	Genome-Wide Association Studies of Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4255-4267.	1.6	159
52	<i>BRCA</i> Mutations and Risk of Prostate Cancer in Ashkenazi Jews. <i>Clinical Cancer Research</i> , 2004, 10, 2918-2921.	7.0	156
53	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018, 36, 414-424.	1.6	155
54	Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for <i>CH</i> <i>EK</i> <i>2</i> *1100delC Carriers. <i>Journal of Clinical Oncology</i> , 2016, 34, 2750-2760.	1.6	152

#	ARTICLE	IF	CITATIONS
55	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017, 35, 2240-2250.	1.6	152
56	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. <i>JAMA Oncology</i> , 2017, 3, 1634.	7.1	148
57	BRCA Challenge: BRCA Exchange as a global resource for variants in <i>BRCA1</i> and <i>BRCA2</i> . <i>PLoS Genetics</i> , 2018, 14, e1007752.	3.5	148
58	Risk of Endometrial Carcinoma Associated with <i>BRCA</i> Mutation. <i>Gynecologic Oncology</i> , 2001, 80, 395-398.	1.4	147
59	Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. <i>Journal of Clinical Oncology</i> , 2016, 34, 4071-4078.	1.6	147
60	Breast cancer phenotype in women with <i>TP53</i> germline mutations: a Li-Fraumeni syndrome consortium effort. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1125-1130.	2.5	144
61	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. <i>Clinical Cancer Research</i> , 2020, 26, 3239-3247.	7.0	135
62	Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in <i>BRCA1</i> or <i>BRCA2</i> . <i>Cancer</i> , 2005, 103, 44-51.	4.1	132
63	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1228.	7.1	132
64	Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. <i>Gynecologic Oncology</i> , 2003, 89, 281-287.	1.4	130
65	Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 3469-3476.	1.5	125
66	Hereditary breast cancer. <i>Current Problems in Surgery</i> , 2001, 38, 387-480.	1.1	124
67	Cancer Genomics and Inherited Risk. <i>Journal of Clinical Oncology</i> , 2014, 32, 687-698.	1.6	121
68	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
69	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. <i>American Journal of Human Genetics</i> , 2016, 98, 801-817.	6.2	113
70	Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. <i>BMC Medical Genomics</i> , 2017, 10, 33.	1.5	111
71	Estimated Risk of Radiation-Induced Breast Cancer From Mammographic Screening for Young <i>BRCA</i> Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2009, 101, 205-209.	6.3	108
72	Screening for Germline <i>EGFR</i> T790M Mutations Through Lung Cancer Genotyping. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1049-1052.	1.1	108

#	ARTICLE	IF	CITATIONS
73	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. <i>Npj Breast Cancer</i> , 2017, 3, 22.	5.2	108
74	Population Frequency of Germline <i>BRCA1/2</i> Mutations. <i>Journal of Clinical Oncology</i> , 2016, 34, 4183-4185.	1.6	107
75	Frequency of CHEK2*1100delC in New York breast cancer cases and controls. <i>BMC Medical Genetics</i> , 2003, 4, 1.	2.1	106
76	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i> . <i>Journal of the National Cancer Institute</i> , 2020, 112, 1242-1250.	6.3	106
77	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003173.	3.5	105
78	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO). <i>Clinical Cancer Research</i> , 2019, 25, 2717-2724.	7.0	102
79	Comparison of screening CEDM and MRI for women at increased risk for breast cancer: A pilot study. <i>European Journal of Radiology</i> , 2017, 97, 37-43.	2.6	98
80	Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from <i>BRCA1</i> heterozygotes. <i>Cancer</i> , 2000, 89, 383-390.	4.1	97
81	Pleomorphic Characteristics of a Germ-Line <i>KIT</i> Mutation in a Large Kindred with Gastrointestinal Stromal Tumors, Hyperpigmentation, and Dysphagia. <i>Clinical Cancer Research</i> , 2004, 10, 1250-1254.	7.0	97
82	Refined histopathological predictors of <i>BRCA1</i> and <i>BRCA2</i> mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. <i>Breast Cancer Research</i> , 2014, 16, 3419.	5.0	97
83	Alterations in <i>PTEN</i> and <i>ESR1</i> promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , 2020, 1, 382-393.	13.2	96
84	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2022, 40, 1231-1258.	1.6	96
85	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	12.8	93
86	A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 154-160.	2.4	91
87	Epithelial lesions in prophylactic mastectomy specimens from women with <i>BRCA</i> mutations. <i>Cancer</i> , 2003, 97, 1601-1608.	4.1	90
88	The Landscape of Somatic Genetic Alterations in Breast Cancers From <i>ATM</i> Germline Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1030-1034.	6.3	90
89	Genetic Analysis of the Early Natural History of Epithelial Ovarian Carcinoma. <i>PLoS ONE</i> , 2010, 5, e10358.	2.5	90
90	Male breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: pathology data from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> . <i>Breast Cancer Research</i> , 2016, 18, 15.	5.0	88

#	ARTICLE	IF	CITATIONS
91	A Prospective, Longitudinal Study of the Functional Status and Quality of Life of Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1119-1124.	2.6	86
92	Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. <i>Breast Cancer Research and Treatment</i> , 2006, 98, 343-348.	2.5	85
93	Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. <i>Cancer</i> , 2012, 118, 493-499.	4.1	83
94	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	1.6	83
95	Heterogeneous Loss of the Wild-Type BRCA Allele in Human Breast Tumorigenesis. <i>Annals of Surgical Oncology</i> , 2007, 14, 2510-2518.	1.5	82
96	Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report. <i>Clinical Cancer Research</i> , 2010, 16, 755-763.	7.0	82
97	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	4.5	82
98	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
99	Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation-Negative Hereditary Breast Cancer Families. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1382-1384.	6.3	80
100	Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. <i>JAMA Network Open</i> , 2020, 3, e208501.	5.9	79
101	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	9.4	79
102	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv315.	6.3	77
103	Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 565-571.	2.5	77
104	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. <i>European Journal of Cancer</i> , 2019, 120, 20-30.	2.8	75
105	Health literacy, numeracy, and interpretation of graphical breast cancer risk estimates. <i>Patient Education and Counseling</i> , 2011, 83, 92-98.	2.2	74
106	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. <i>Nature Cancer</i> , 2021, 2, 357-365.	13.2	74
107	Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: A WECARE Study Report. <i>European Journal of Cancer</i> , 2013, 49, 2979-2985.	2.8	72
108	A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients. <i>European Journal of Cancer</i> , 2018, 101, 12-19.	2.8	72

#	ARTICLE	IF	CITATIONS
109	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2011, 13, R110.	5.0	71
110	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011, 20, 4693-4706.	2.9	71
111	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1683-1692.	6.3	66
112	Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. <i>Cancer</i> , 2012, 118, 4944-4952.	4.1	64
113	Variation in Anastrozole Metabolism and Pharmacodynamics in Women with Early Breast Cancer. <i>Cancer Research</i> , 2010, 70, 3278-3286.	0.9	63
114	Germline EGFR T790M Mutation Found in Multiple Members of a Familial Cohort. <i>Journal of Thoracic Oncology</i> , 2014, 9, 554-558.	1.1	63
115	Effect of Mammography on Breast Cancer Risk in Women with Mutations in BRCA1 or BRCA2. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2311-2313.	2.5	60
116	Revealing the Incidentalome When Targeting the Tumor Genome. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 795.	7.4	60
117	Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. <i>Journal of Clinical Oncology</i> , 2020, 38, 1398-1408.	1.6	60
118	Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. <i>Cancer</i> , 2013, 119, 1344-1348.	4.1	58
119	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2014, 16, 3416.	5.0	57
120	The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/Overexpressed/Amplified Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1216-1222.	1.6	56
121	American Society of Clinical Oncology Policy Statement: The Role of the Oncologist in Cancer Prevention and Risk Assessment. <i>Journal of Clinical Oncology</i> , 2009, 27, 986-993.	1.6	55
122	Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 1792-1793.	27.0	55
123	Increased Progesterone Receptor Expression in Benign Epithelium of BRCA1-Related Breast Cancers. <i>Cancer Research</i> , 2004, 64, 5051-5053.	0.9	51
124	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). <i>PLoS ONE</i> , 2012, 7, e42380.	2.5	51
125	TSPYL5 SNPs: Association with Plasma Estradiol Concentrations and Aromatase Expression. <i>Molecular Endocrinology</i> , 2013, 27, 657-670.	3.7	49
126	Genetic Testing Awareness and Attitudes among Latinos: Exploring Shared Perceptions and Gender-Based Differences. <i>Public Health Genomics</i> , 2016, 19, 34-46.	1.0	49



#	ARTICLE	IF	CITATIONS
127	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	3.5	47
128	Breast MRI for Women With Hereditary Cancer Risk. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 1368.	7.4	45
129	Ductal lavage in patients undergoing mastectomy for mammary carcinoma. <i>Cancer</i> , 2003, 98, 2170-2176.	4.1	44
130	A Comparison of Bilateral Breast Cancers in BRCA Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1534-1538.	2.5	44
131	Inherited Predisposition to Gastrointestinal Stromal Tumor. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 1-13.	2.2	44
132	Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50</i>	2.0	44
133	Susceptibility Loci Associated with Specific and Shared Subtypes of Lymphoid Malignancies. <i>PLoS Genetics</i> , 2013, 9, e1003220.	3.5	44
134	Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1513-1520.	1.6	44
135	The context-specific role of germline pathogenicity in tumorigenesis. <i>Nature Genetics</i> , 2021, 53, 1577-1585.	21.4	44
136	Feasibility Trial of Letrozole in Combination With Bevacizumab in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 628-633.	1.6	43
137	Twenty-one "gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status. <i>Cancer</i> , 2016, 122, 1178-1184.	4.1	42
138	Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 61-66.	2.5	42
139	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. <i>Cancer Discovery</i> , 2016, 6, 1267-1275.	9.4	41
140	A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. <i>Future Oncology</i> , 2017, 13, 307-320.	2.4	41
141	Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. <i>BJU International</i> , 2012, 109, 713-719.	2.5	40
142	Multigene Panel Testing: Planning the Next Generation of Research Studies in Clinical Cancer Genetics. <i>Journal of Clinical Oncology</i> , 2014, 32, 1987-1989.	1.6	40
143	Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers. <i>Oncogene</i> , 2002, 21, 7034-7041.	5.9	39
144	Homologous recombination DNA repair defects in PALB2-associated breast cancers. <i>Npj Breast Cancer</i> , 2019, 5, 23.	5.2	39

#	ARTICLE	IF	CITATIONS
145	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.9	39
146	Clinical Considerations in the Management of Individuals at Risk for Hereditary Breast and Ovarian Cancer. <i>Cancer Control</i> , 2002, 9, 457-465.	1.8	38
147	Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. <i>Gynecologic Oncology</i> , 2003, 89, 440-446.	1.4	38
148	Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. <i>Steroids</i> , 2015, 99, 32-38.	1.8	38
149	Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. <i>Npj Breast Cancer</i> , 2021, 7, 96.	5.2	38
150	Assessment of SLX4 Mutations in Hereditary Breast Cancers. <i>PLoS ONE</i> , 2013, 8, e66961.	2.5	37
151	Hereditary ovarian cancer in Ashkenazi Jews. <i>Familial Cancer</i> , 2004, 3, 259-264.	1.9	36
152	COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. <i>Breast Cancer Research</i> , 2013, 15, 402.	5.0	36
153	Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?. <i>BMC Medicine</i> , 2014, 12, 140.	5.5	36
154	Breast Cancer Screening Strategies for Women With <i>ATM</i> , <i>CHEK2</i> , and <i>PALB2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2022, 8, 587.	7.1	36
155	Evaluation of germline PTEN mutations in endometrial cancer patients. <i>Gynecologic Oncology</i> , 2005, 96, 21-24.	1.4	35
156	Genome-wide Association Studies of Cancer Predisposition. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 973-996.	2.2	34
157	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	2.5	34
158	Germline <i>SDHA</i> mutations in children and adults with cancer. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002584.	1.2	33
159	Adjuvant treatment recommendations in older women with breast cancer—A survey of oncologists. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 61, 255-260.	4.4	32
160	Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. <i>Journal of Medical Genetics</i> , 2019, 56, 347-357.	3.2	32
161	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	1.3	32
162	Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 5754-5761.	7.0	31

#	ARTICLE	IF	CITATIONS
163	The TP53 mutational spectrum and frequency of CHEK2*1100delC in Liâ€“Fraumeni-like kindreds. <i>Familial Cancer</i> , 2005, 4, 177-181.	1.9	31
164	Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 273-279.	2.5	31
165	A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. <i>Genetics in Medicine</i> , 2018, 20, 1324-1327.	2.4	31
166	Protein-altering germline mutations implicate novel genes related to lung cancer development. <i>Nature Communications</i> , 2020, 11, 2220.	12.8	31
167	Functional redundancy of exon 12 of <i>BRCA2</i> revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant. <i>Human Mutation</i> , 2009, 30, 1543-1550.	2.5	30
168	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	6.3	30
169	BRCA Mutations in Women with Ductal Carcinoma In situ. <i>Clinical Cancer Research</i> , 2007, 13, 4306-4310.	7.0	29
170	Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 487-496.	2.5	29
171	Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. <i>Genetics in Medicine</i> , 2021, 23, 2105-2113.	2.4	29
172	Germline PALB2 mutation analysis in breast-pancreas cancer families. <i>Journal of Medical Genetics</i> , 2011, 48, 523-525.	3.2	28
173	A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicinâ€“Cyclophosphamide (AC) Followed by Nanoparticle Albuminâ€“Bound Paclitaxel in Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3398-3407.	7.0	28
174	Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	28
175	Breast Cancer Surveillance in Women with Hereditary Risk Due to BRCA1 or BRCA2 Mutations. <i>Clinical Breast Cancer</i> , 2004, 5, 260-268.	2.4	27
176	Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 127-135.	2.5	27
177	The genomic landscape of metastatic histologic special types of invasive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 53.	5.2	27
178	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	5.0	26
179	Fumarate hydratase <i>FH</i> c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. <i>Human Mutation</i> , 2020, 41, 103-109.	2.5	25
180	Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas. <i>Journal of Thoracic Oncology</i> , 2020, 15, 655-660.	1.1	25

#	ARTICLE	IF	CITATIONS
181	Yoga for Chemotherapy-Induced Peripheral Neuropathy and Fall Risk: A Randomized Controlled Trial. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa048.	2.9	24
182	Ovarian carcinoma screening in women at intermediate risk. <i>Cancer</i> , 2005, 104, 314-320.	4.1	23
183	Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From <i>BRCA1/2</i> -Associated Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4224-4226.	1.6	23
184	A Nonsynonymous Polymorphism in <i>IRS1</i> Modifies Risk of Developing Breast and Ovarian Cancers in <i>BRCA1</i> and Ovarian Cancer in <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1362-1370.	2.5	23
185	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. <i>Modern Pathology</i> , 2020, 33, 2221-2232.	5.5	23
186	The 6q22.33 Locus and Breast Cancer Susceptibility. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2468-2475.	2.5	22
187	Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 497-506.	2.5	22
188	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	2.5	22
189	Rare De Novo Germline Copy-Number Variation in Testicular Cancer. <i>American Journal of Human Genetics</i> , 2012, 91, 379-383.	6.2	21
190	Radiation Treatment, <i>ATM</i> , <i>BRCA1/2</i> , and <i>CHEK2</i> *1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1275-1279.	6.3	21
191	Cancer-Causative Mutations Occurring in Early Embryogenesis. <i>Cancer Discovery</i> , 2022, 12, 949-957.	9.4	21
192	Estrogen Receptor-Beta Expression in Hereditary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 3752-3753.	1.6	20
193	The Landscape of Somatic Genetic Alterations in Breast Cancers from <i>CHEK2</i> Germline Mutation Carriers. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz027.	2.9	20
194	Risks to Relatives in Genomic Research: A Duty to Warn?. <i>American Journal of Bioethics</i> , 2012, 12, 12-14.	0.9	19
195	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	6.4	19
196	Endometrial Cancers in <i>BRCA1</i> or <i>BRCA2</i> Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	3.0	19
197	A case-only study to identify genetic modifiers of breast cancer risk for <i>BRCA1/BRCA2</i> mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	12.8	19
198	PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. <i>The Cochrane Library</i> , 2021, 2021, CD011395.	2.8	19

#	ARTICLE	IF	CITATIONS
199	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	6.3	19
200	Association of breast cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	2.5	18
201	Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Genetics in Medicine</i> , 2001, 3, 422-425.	2.4	17
202	<i>SLCO1B1</i> polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 189-199.	2.5	17
203	Germline <i>BRCA2</i> mutations detected in pediatric sequencing studies impact parents' evaluation and care. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001925.	1.2	17
204	Characterization of a novel germline <i>PALB2</i> duplication in a hereditary breast and ovarian cancer family. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 447-456.	2.5	16
205	Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among <i>BRCA1/2</i> mutation noncarriers with newly diagnosed breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 297-306.	2.5	16
206	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	2.4	16
207	Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. <i>JCI Insight</i> , 2020, 5, .	5.0	16
208	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. <i>European Urology Oncology</i> , 2021, 4, 993-1000.	5.4	16
209	Protecting the privacy of third-party information: Recommendations for social and behavioral health researchers. <i>Social Science and Medicine</i> , 2007, 64, 213-222.	3.8	15
210	Absence of genomic <i>BRCA1</i> and <i>BRCA2</i> rearrangements in Ashkenazi breast and ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 581-585.	2.5	15
211	New Pharmacogenomic Paradigm in Breast Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2010, 28, 4665-4666.	1.6	14
212	Mosaic partial deletion of the <i>PTEN</i> gene in a patient with Cowden syndrome. <i>Familial Cancer</i> , 2014, 13, 459-467.	1.9	14
213	Educational and Psychosocial Support Needs in Lynch Syndrome: Implementation and Assessment of an Educational Workshop and Support Group. <i>Journal of Genetic Counseling</i> , 2017, 26, 232-243.	1.6	14
214	Oncology Patients' Perspectives on Remote Patient Monitoring for COVID-19. <i>JCO Oncology Practice</i> , 2021, 17, e1278-e1285.	2.9	14
215	Broad Application of Multigene Panel Testing for Breast Cancer Susceptibility "Pandora's Box Is Opening Wider. <i>JAMA Oncology</i> , 2019, 5, 1687.	7.1	13
216	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. <i>Clinical Cancer Research</i> , 2022, 28, 404-413.	7.0	13

#	ARTICLE	IF	CITATIONS
217	Treatment of Hereditary Breast Cancer. <i>Seminars in Oncology</i> , 2007, 34, 384-391.	2.2	12
218	Prolonged Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel in Breast Cancer Is Feasible. <i>Clinical Breast Cancer</i> , 2008, 8, 418-424.	2.4	12
219	Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 223-227.	7.0	11
220	Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 625-634.	2.5	11
221	Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer. <i>Cancer Medicine</i> , 2021, 10, 5163-5174.	2.8	11
222	Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than <i>BRCA1</i> or <i>BRCA2</i> . <i>Journal of Clinical Oncology</i> , 2021, 39, 2528-2534.	1.6	11
223	What Women with Breast Cancer Discuss with Clinicians About Risk for Their Adolescent Daughters. <i>Journal of Psychosocial Oncology</i> , 2012, 30, 484-502.	1.2	10
224	Differences between screen-detected and interval breast cancers among BRCA mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 141-148.	2.5	10
225	Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e031092.	1.9	10
226	Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between <i>SLC38A7</i> and <i>ALPPL2</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 219-227.	4.7	10
227	Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio $\leq 2.0$ and Average HER2 Copy Number $\geq 4.0$ and $\leq 6.0$ . <i>Archives of Pathology and Laboratory Medicine</i> . 2020, 144, 597-601.	2.5	10
228	Prevalence and Characterization of Biallelic and Monoallelic <i>NTHL1</i> and <i>MSH3</i> Variant Carriers From a Pan-Cancer Patient Population. <i>JCO Precision Oncology</i> , 2021, 5, 455-465.	3.0	10
229	Penetrance of male breast cancer susceptibility genes: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 31-38.	2.5	10
230	Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1450-1459.	2.5	10
231	Juvenile Polyposis Syndrome Presenting With Familial Gastric Cancer and Massive Gastric Polyposis. <i>Journal of Clinical Oncology</i> , 2012, 30, e229-e232.	1.6	9
232	Identification and Functional Characterization of <i>EGFR</i> V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. <i>JCO Precision Oncology</i> , 2017, 1, 1-10.	3.0	9
233	Broadening Criteria for BRCA1/2 Evaluation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 619.	7.4	9
234	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. <i>JCO Precision Oncology</i> , 2020, 4, 916-925.	3.0	9

#	ARTICLE	IF	CITATIONS
235	Comprehensive Breast Cancer Risk Assessment for <i>CHEK2</i> and <i>ATM</i> Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model. <i>JCO Precision Oncology</i> , 2021, 5, 1073-1081.	3.0	9
236	Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. <i>Npj Breast Cancer</i> , 2021, 7, 135.	5.2	9
237	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. <i>Npj Breast Cancer</i> , 2022, 8, 37.	5.2	9
238	Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 4706-4713.	1.5	9
239	Pilot study of rapid MR pancreas screening for patients with BRCA mutation. <i>European Radiology</i> , 2019, 29, 3976-3985.	4.5	8
240	BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5559-5559.	1.6	8
241	Inherited Predisposition to Cancer: Introduction and Overview. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 793-797.	2.2	7
242	RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 522-523.	6.3	7
243	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	3.0	7
244	Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel <i>BRCA1/2</i> Genetic Risk Modifier Test. <i>Public Health Genomics</i> , 2020, 23, 6-19.	1.0	7
245	Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 362-371.	2.5	7
246	Inherited predisposition to endometrial cancer: Moving beyond Lynch syndrome. <i>Cancer</i> , 2015, 121, 644-647.	4.1	6
247	Decision-Making Preferences About Secondary Germline Findings That Arise From Tumor Genomic Profiling Among Patients With Advanced Cancers. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	3.0	6
248	PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1274-1281.	3.7	6
249	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. <i>Journal of the National Cancer Institute</i> , 2021, , .	6.3	6
250	Do Women Remain at Risk Even If They Do Not Inherit a Familial <i>BRCA1/2</i> Mutation?. <i>Journal of Clinical Oncology</i> , 2011, 29, 4477-4478.	1.6	5
251	Should the Presence of Germline <i>BRCA1/2</i> Mutations Influence Treatment Selection in Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2011, 29, 3724-3726.	1.6	5
252	Characterization of a novel germline <i>BRCA1</i> splice variant, c.5332+4delA. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 543-550.	2.5	5

#	ARTICLE	IF	CITATIONS
253	Tolerability of Breast Radiotherapy Among Carriers of <i>ATM</i> Germline Variants. <i>JCO Precision Oncology</i> , 2021, 5, 227-234.	3.0	5
254	A Novel Adverse Event Associated with Olaparib Therapy in a Patient with Metastatic Breast Cancer. <i>Case Reports in Oncological Medicine</i> , 2018, 2018, 1-5.	0.3	4
255	Points to Consider Regarding Risk-Reducing Mastectomy in High-, Moderate-, and Low-Penetrance Gene Carriers. <i>Annals of Surgical Oncology</i> , 2022, 29, 5821-5825.	1.5	4
256	Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4267-4277.	7.0	4
257	Is breast conservation a reasonable option for women with BRCA-associated breast cancer?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 10-11.	4.3	3
258	Oophorectomy for BRCA1 ER-negative disease—an open debate. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 505-506.	27.6	3
259	Seizing the Opportunity: Recognition and Management of Hereditary Cancer Predisposition. <i>Seminars in Oncology</i> , 2007, 34, 367-368.	2.2	2
260	Response: Table 1.. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw173.	6.3	2
261	The Role of Genetic Counseling in Familial and Sporadic Cancer: Considerations, Challenges, and Collaboration. <i>Annals of Internal Medicine</i> , 2017, 167, 884.	3.9	2
262	Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers. <i>Gynecologic Oncology</i> , 2021, 161, 521-526.	1.4	2
263	Frequency of actionable cancer predisposing germline mutations in patients with lung cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1504-1504.	1.6	2
264	Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1262-1263.	1.6	1
265	Considerations in genetic counseling for inherited breast cancer predisposition. <i>Seminars in Radiation Oncology</i> , 2002, 12, 362-370.	2.2	0
266	Preface. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, xi-xii.	2.2	0
267	Genetic Epidemiology of Breast Cancer. , 2013, , 1113-1125.		0
268	Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for locally advanced or metastatic breast cancer. <i>The Cochrane Library</i> , 0, , .	2.8	0
269	Understanding the Paradigm Challenges Posed by Multiplex Panel Testing for Cancer Susceptibility. <i>Current Genetic Medicine Reports</i> , 2014, 2, 250-254.	1.9	0
270	Moderate-Penetrance Predisposition to Breast Cancer. <i>Current Breast Cancer Reports</i> , 2018, 10, 232-239.	1.0	0



#	ARTICLE	IF	CITATIONS
271	The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriersK.A. Metcalfe, H.T. Lynch, P. Chadirian, N. Tung, I.A. Olivotto, W.D. Foulkes, E. Warner, O. Olopade, A. Eisen, B. Weber, et al. Gynecol Oncol 2005;96:222â€“26. Women's Oncology Review, 2005, 5, 163-164.	0.0	0
272	Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies. Blood, 2015, 126, 2447-2447.	1.4	0
273	Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. Pharmacogenetics and Genomics, 2021, 31, 1-9.	1.5	0